EP Patent

EP2094291A1 — Dimeric prolactin receptor ligands

Assigned to Novo Nordisk AS · Expires 2009-09-02 · 17y expired

What this patent protects

The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer.

USPTO Abstract

The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer.

Drugs covered by this patent

pilocarpine-hydrochloride (PILOCARPINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP2094291A1
Jurisdiction: EP
Classification: —
Expires: 2009-09-02
Drug substance claim: No
Drug product claim: No
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.